

Atazanavir/ritonavir

S

QTc prolongation following off-label treatment: case report

In a retrospective study involving 446 patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) who were admitted to a hospital in Malaysia between 30 March 2020 and 30 April 2020, one patient [*age and sex not stated*] was described, who developed QTc prolongation following off-label treatment with atazanavir/ritonavir for the SARS-CoV-2 infection.

The patient with SARS-CoV-2 infection, was hospitalised and started receiving off-label treatment with atazanavir/ritonavir 300/100mg once daily [*dosage and route not stated*]. However, the patient developed QTc prolongation secondary to the atazanavir/ritonavir therapy [*duration of treatment to reaction onset and outcome not stated*].

Koh HM, et al. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19. *Journal of Clinical Pharmacy and Therapeutics* 46: 800-806, No. 3, Jun 2021. Available from: URL: <http://doi.org/10.1111/jcpt.13356> 803575054